An interventional study of Transcutaneous Electrical Nerve Stimulator (TENS) in Overactive Bladder, sponsored by Rajeev Chaudhry. Withdrawn at 1 site in United States. Open to participants aged 5 Years to 16 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-12-27.
Sponsored by Rajeev Chaudhry · Not applicable, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 333 studies in Urinary Bladder, Overactive with a site in United States — 40 open to participants now, 48 under way, 2 of them phase 3. Urinary Bladder, Overactive · United States.
Among the 333 studies in Urinary Bladder, Overactive with a site in United States, this one is the 278th largest by enrollment of the 288 interventional ones that give a count, is one of 14 that started in 2014, is one of 113 with no phase, and was the 146th registered.
858 studies on the registry are indexed under Urinary Bladder, Overactive; 126 are open to participants now.
Browse Urinary Bladder, Overactive studies →40 of the 333 studies in Urinary Bladder, Overactive with a site in United States are open now. Recruiting first, the newest first:
Mayo Clinic · Sites in United States
Ages 21+ · Women only
Vensica Therapeutics Ltd. · Sites in United States
Ages 18–80 · Women only
The Cleveland Clinic · Sites in United States
Ages 18+ · Women only
Loma Linda University · Sites in United States
Ages 18–89
Stimuli Technology · Sites in United States, Canada
Ages 22+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 73 Urinary Bladder, Overactive studies recruiting now, 44 (60%) set no upper age limit and 15 (21%) stop at 75 or younger; 6 take children under 18; 8 take healthy volunteers.
This study: 5 Years to 16 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
333 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 26 · Phase 2 35 · Phase 3 52 · Phase 4 71
First in 2002; this study’s year is marked. 14 started in 2014.
By drug class, each counting the studies that test any of its medicines:
Median enrollment 66 across the 288 interventional studies, 91 across the 43 observational. Of the 259 that completed or were terminated, 134 (52%) have results posted.
This tab as a report to print or save as PDF → With an account.
153 of 333 have an industry lead sponsor. The 10 most frequent:
Rajeev Chaudhry is the lead sponsor of 3 studies on the registry; none are open to participants now.
Rajeev Chaudhry has 1 study filed under Urinary Bladder, Overactive — fewer than ten, so there is no comparison to draw.
19 of the studies in Urinary Bladder, Overactive with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06797245Medstar Health Research InstituteAPPROVE Trial: Evaluating a Prescription Digital Therapeutic for Treatment of OAB in Women | 2026-11 |
| NCT07387315TriHealth Inc.A Randomized, Placebo-controlled Trial of Nitrous Oxide During In-office Bladder Botox Injections | 2026-11 |
| NCT07335484Axonics, Inc.Aquarius Pilot Study to Evaluate the New Axonics Trial System | 2026-11 |
| NCT07405554Endeavor HealthZinc Supplementation With Botulinum Toxin for Overactive Bladder | 2026-12 |
| NCT05200923MedtronicNeuroPelvic Health Electrically Evoked Recording (PEER) 2 Study | 2026-12-18 |
Add all 19 to your calendar (.ics) → With an account.
Among the 333 studies in Urinary Bladder, Overactive with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
To determine the effects of electrical stimulation of the nerves in the foot on overactive bladder conditions in children.
Bladder overactivity in the pediatric population presents a more challenging clinical situation than in adults after failure of medical therapy, as other treatments with proven efficacy such as botulinum injections and interstim sacral nerve stimulators are too invasive for the routine use in children. A non-invasive, effective way to improve overactive bladder in this population would have a great impact on a child's quality of life.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Note: Any patient currently taking medication such as an anti-muscarinic or a tricyclic antidepressant for overactive bladder at time of enrollment will be eligible to participate and will be continued on their usual medication and dosage throughout the study.
Transcutaneous Electrical Nerve Stimulator (TENS) will be applied to the foot via skin surface electrodes for a minimum of 2 hours per day for 1 week to 20 subjects. Subjects will be required to keep a daily voiding diary for one week before treatment to establish a control, during the treatment week and for one week after treatment. Subjects will also be asked to complete a validated questionnaire prior to treatment, during treatment week and one week after treatment. The primary outcomes of this study are improvement in objective measures of frequency as indicated by voiding diary and subjective symptom improvement based on questionnaire comparison.
Device: Transcutaneous Electrical Nerve Stimulator (TENS)
Electrical stimulation will be applied to the foot via skin surface electrodes for a minimum of 2 hours per day for 1 week to 20 subjects.
Number of participants with decreased urinary frequency
Foot stimulation decreases urinary frequency measured by a daily voiding diary.
Time frame: 3 weeks
Number of participants with improved over active bladder symptoms
Foot stimulation improves OAB symptoms over the course of 3-week period, with foot stimulation applied during the second week measured by a validated symptom survey
Time frame: 3 weeks
The record gives a start of Sep 2014, a primary completion of Dec 2020 and a completion of Dec 2020. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is withdrawn, as verified in Dec 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.